THE GLOBAL ERECTILE DYSFUNCTION TREATMENT MARKET IS PROJECTED TO SURPASS USD 4.46 BILLION BY 2029 FROM USD 4.72 BILLION IN 2023

The Erectile Dysfunction Treatment Market Size, Share, & Trends Analysis Report by

  • Product: Drugs and Devices
  • ROA – Drugs: Oral Drugs, Penile Injections & Suppositories, and Topical Formulation
  • Distribution Channel – Drugs: Retail Pharmacies, Hospital Pharmacies, and Online Portals
  • Type – Devices: Penile Implants, Vacuum Constriction Devices, Shock Wave Therapy, and Others
  • Geography: North America, Europe, APAC, Latin America, and Middle East & Africa

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

122 Pages

icon-table

04 Tables

icon-chart

34 Charts

icon-region

5 Regions

icon-country

16 Countries

icon-company

47 Companies

icon-market

5 Market Segment

ERECTILE DYSFUNCTION TREATMENT MARKET REPORT SCOPE

Report Attribute Details
Market Size (2029) USD 4.46 Billion
Market Size(2023) USD 4.72 Billion
CAGR (2023-2029) (0.94%)
Base Year 2023
Historic Year 2020-2022
Forecast Year 2024-2029
Market Segments Product, ROA – Drugs, Distribution Channel – Drugs, Type – Devices, and Geography
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Key Vendors Coloplast, Boston Scientific, Pfizer, Eli Lilly and Company, Teva Pharmaceuticals, and Bayer

INDUSTRY OVERVIEW

The global erectile dysfunction treatment market was valued at USD 4.72 billion in 2023 and is expected to reach USD 4.46 billion by 2029, registering a negative CAGR of -0.94% during the forecast period. A high prevalence of ED and associated chronic diseases such as diabetes, benign prostate hyperplasia, prostate cancer, and CVDs, which can, in turn, pose as a high-risk factor for the occurrence of this disease, are key market drivers for the ED market both in developing and developed countries. Further, rising awareness, growing patient willingness to demand medical assistance for disease care and management, and the increasing presence of favorable guidelines that recommend the use of drugs and devices for the treatment of ED are expected to propel the erectile dysfunction treatment market growth during the forecast period. Also, constantly developing and launching innovative products is essential for vendors operating in this steadily competitive market to achieve healthy sales growth and increase industry share.

MARKET TRENDS & DRIVERS

New Device Technologies in ED Treatment
The increasing focus of manufacturers on research and innovation led to the development of advancements in the treatment of erectile dysfunction. Shock wave therapy recently emerged into the market, proving its safety and efficacy with no adverse effects. Furthermore, innovations by vendors, such as magnetic therapy and the development of vibrators, are also likely to boost the growth of the erectile dysfunction treatment market.

Advancements in ED Treatment Devices
The increasing innovations in pharmaceutical research deliver advancements in ED devices. Widely used ED devices include penile implants, vacuum constriction devices, and shockwave therapy. Penile implants cover a major part of the industry share due to their high physician recommendation. Moreover, adverse effects are associated with the pharmacological therapy of ED and permanent treatment.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT
The drugs product segment dominated the global erectile dysfunction treatment market share in 2023. The ED drugs market segment comprises oral therapies, topical therapies, intraurethral suppositories, and penile injection therapies. Among the three sub-segments, the oral drugs sub-segment dominated the ROA segment. Oral therapies contain PDE-5 inhibitors, which are recognized as a first-line treatment option by medical professionals and government bodies for the treatment of ED. The growth of the ED drugs market is attributed to the high prevalence of vascular and chronic diseases such as diabetes, hypertension, psychological disorders, etc. Furthermore, alcohol consumption, secondary lifestyle, and cigarette smoking are contributing to the increase in the prevalence of ED. The aging population is also increasing the demand for ED drugs in the industry.

INSIGHTS BY ROA – DRUGS
The global erectile dysfunction treatment market by ROA – drugs is segmented into oral drugs, penile injections & suppositories, and topical formulation. In 2023, the oral drugs segment accounted for the most prominent share of the market and is projected to continue its dominance during the forecast period. The significant share of this segment can be mainly attributed to the brand value of currently marketed PDE5 inhibitor drugs, which facilitate high uptake of these drugs by ED patients, especially for self-management of the condition. Furthermore, oral drugs are found to be more effective & safer and are considered first-line therapy drugs in the treatment of ED. The only class of drugs available are phosphodiesterase (PDE)-5 inhibitors, which include sildenafil, tadalafil, vardenafil, avanafil, udenafil, lodenafil, and mirodenafil. Further, new drugs such as Stendra (avanafil) were observed to have several advantages compared to the old drugs, such as decreased side effects & interactions and rapid onset of action. At present, Stendra is the only drug available as a branded drug version for ED.

INSIGHTS BY DISTRIBUTION CHANNEL – DRUGS
The retail pharmacies distribution channel is projected to hold the most significant share of the global erectile dysfunction treatment market in 2023. The retail pharmacies segment is expected to lead the industry due to the easy availability of erectile dysfunction drugs at retail stores. Furthermore, the expiration of patent protection for blockbuster drugs, including Viagra, Cialis, and Levitra, is increasing their generic sales through retail pharmacies, where they can be purchased easily without any prescription.

INSIGHTS BY TYPE – DEVICES
The global erectile dysfunction treatment market by type – devices is segmented into penile implants, vacuum constriction devices, shock wave therapy, and others. The penile implant-type–devices segment had the most significant global market share in 2023. Penile implantations are recommended when the patient fails to respond through oral PDE-5 inhibitors or penile injections. Although penile implantations are considered the last option by physicians compared to drugs, the demand for these implantations is increasing in the industry due to their high efficacy, providing up to 90% satisfactory erection in the patient population. Furthermore, several innovations were made in the ED devices industry. For Instance, an innovative penile prosthesis based on a novel nickel-titanium shape memory alloy (SMA), alternating between rigid configuration and flaccid on heat application, can mimic the erection without needing a pump or reservoir. A study comparing with AMS 700 demonstrated that SMA showed comparable results, which may provide a new option for treating ED.

GEOGRAPHICAL ANALYSIS

North America was the largest geographical segment of the global erectile dysfunction treatment market, with a share of over 33% in 2023. The presence of a large proportion of the ED population, coupled with better access to ED, especially generic drugs, is the primary factor for its high industry share. The increased awareness of ED among young and middle-aged men through several public and private sponsored health campaigns, as well as the advent of new ED drugs, especially OTC drugs, is projected to enable industry growth in the region. Furthermore, The U.S. is the major revenue contributor to the North American erectile dysfunction treatment market. The demand for ED treatment in the United States is increasing at a healthy rate owing to the significant rise in the prevalence/incidence of erectile dysfunction in adult men.

The prevalence of ED across European countries is likely to rise during the forecast period, which, in turn, is expected to contribute to the increasing ED treatment pool, thereby driving the size of the erectile dysfunction treatment market. The growing prevalence of diseases associated with the risk of ED as a co-morbid condition and the rise in acute and chronic stress will drive the ED prevalence population. Furthermore, factors like a huge patient population, well-established healthcare infrastructure, and rising healthcare expenditure are projected to support the growth of the ED treatment industry in the APAC region. The prevalence rate of ED is significantly higher in the APAC region than in other regions worldwide. The region is also witnessing a significant increase in ED incidence due to the growing burden of chronic conditions, which, in turn, are associated with the high risk of ED occurrence.

VENDOR LANDSCAPE

The global erectile dysfunction treatment market is characterized by pharmaceutical companies, generic manufacturers, and device manufacturers. Companies in the market offer generic drugs, topical cream formulations, and non-invasive methods. Further, the consumption of ED drugs and devices is the highest in the U.S. and Europe. The demand for ED treatment is also anticipated to grow drastically in developing regions, especially in the APAC region, due to an unsatisfied patient pool, large unmet demand, and increased awareness. As a result, various players are growing their businesses and investing a huge amount in APAC due to considerable growth potential.

Coloplast, Boston Scientific, Pfizer, Eli Lilly and Company, Teva Pharmaceuticals, and Bayer are leading players in the global erectile dysfunction treatment market. Further, Coloplast is a global company developing products and services for personal and private medical conditions. It operates through three reportable segments: chronic care, interventional urology, and wound & skin care. Interventional urology markets urological products, including penile implants such as Titan OTR & Genesis, used in the treatment of erectile dysfunction. Coloplast is a key vendor in manufacturing erectile dysfunction devices.

Frequently Asked Questions

How big is the erectile dysfunction treatment market?

The global erectile dysfunction treatment market size is expected to reach USD 4.46 billion by 2029 from USD 4.72 billion in 2023.

What is the compound annual growth rate of the global erectile dysfunction treatment market?

The global erectile dysfunction treatment market is projected to witness a negative compound annual growth rate of -0.94% during the forecast period.

What are the rising trends in the global erectile dysfunction treatment market?

The rising trends in the erectile dysfunction treatment industry are evolving advancements in ED drug formulation technology, new device technologies in ED treatment, and increasing e-commerce delivery of drugs & devices.

Which region holds the most significant global erectile dysfunction treatment market share?

North America dominated the global erectile dysfunction treatment market share, accounting for over 33% in 2023.

Who are the key players in the global erectile dysfunction treatment market?

Coloplast, Boston Scientific, Pfizer, Eli Lilly and Company, Teva Pharmaceuticals, and Bayer are the key players in the global erectile dysfunction treatment market.

Download Free Sample

The global erectile dysfunction treatment market size is expected to surpass USD 4.46 billion by 2029.

The following factors are likely to contribute to the growth of the erectile dysfunction treatment market during the forecast period:

  • The Advancements in ED Treatment Devices
  • Topical Formulations as a New Treatment for ED
  • High Incidence of ED and Other Chronic Diseases

Base Year: 2023

Forecast Year: 2024-2029

The report considers the present scenario of the global erectile dysfunction treatment market and its market dynamics for 2024−2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.

Key Company Profiles

  • Coloplast
    • Business Overview
    • Product Offerings
  • Boston Scientific
  • Pfizer
  • Eli Lilly and Company
  • Teva Pharmaceuticals
  • Bayer

Other Key Vendors

  • Viatris
    • Business Overview
    • Product Offerings
  • Dong-A Socio
  • VIVUS
  • Cristalia
  • Reddy’s Laboratories Ltd.
  • Aurobindo Pharma
  • Seelos Therapeutics
  • Menarini
  • GSK
  • Futura Medical
  • Sanofi
  • Cipla
  • Lupin
  • Advanz Pharma
  • Sandoz
  • iX Biopharma
  • Dornier MedTech
  • Zephyr Surgical Implants
  • Augusta Medical Systems
  • Metuchen Pharmaceuticals
  • SK Chemicals
  • Endo International
  • Ferring Pharmaceuticals
  • Alembic Pharmaceuticals
  • Guangzhou Pharmaceutical Holdings
  • Launch Medical
  • Bonro Medical
  • Owen Mumford
  • Direx Group
  • Zimmer Medizin Systems
  • MTS Medical UG
  • Medispec
  • Inceler Medical
  • NOVAmedtek
  • WIKKON
  • Top Quality Group
  • Promedon
  • Timm Medical Technologies
  • Global Life Technologies
  • Urology Health Store
  • Hims

Segmentation by Product

  • Drugs
  • Devices

Segmentation by ROA - Drugs

  • Oral Drugs
  • Penile Injections & Suppositories
  • Topical Formulation

Segmentation by Distribution Channel- Drugs

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Portals

Segmentation by Type - Devices

  • Penile Implants
  • Vacuum constriction Devices
  • Shock Wave Therapy
  • Others

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • APAC
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE

CHAPTER 1: ED Treatment Market Overview

  • Executive Summary
  • Key Findings

CHAPTER 2: ED Treatment Market

  • GLOBAL: Projected Revenue of ED Treatment Market (2023-2029; $Millions)

CHAPTER 3: ED Treatment Market Segmentation Data

  • GLOBAL: Projected Revenue by Product type (2022-2028; $ Millions)
  •       ▪ Drugs
  • Route of Administration
  • Oral Drugs
  • Penile Injections
  • Topical Drugs
  • Distribution Channels
  • Retail Stores
  • Hospital Pharmacies
  • Online Portals
  • Type
  • Penile Implants
  • Vacuum Constriction Devices
  • Shock Wave Therapy
  • Others

CHAPTER – 4: Key Regions Overview

  • North America: Projected Revenue of ED Treatment Market (2023-2029; $Millions)
  • Projected Revenue of ED Treatment Market in US
  • Projected Revenue of ED Treatment Market in Canada
  • Europe: Projected Revenue of ED Treatment Market (2023-2029; $Millions)
  • Projected Revenue of ED Treatment Market in UK
  • Projected Revenue of ED Treatment Market in Germany
  • Projected Revenue of ED Treatment Market in France
  • Projected Revenue of ED Treatment Market in Italy
  • Projected Revenue of ED Treatment Market in Spain
  • APAC: Projected Revenue of ED Treatment Market (2023-2029; $Millions)
  • Projected Revenue of ED Treatment Market in Japan
  • Projected Revenue of ED Treatment Market in China
  • Projected Revenue of ED Treatment Market in India
  • Latin America: Projected Revenue of ED Treatment Market (2023-2029; $Millions)
  • Projected Revenue of ED Treatment Market in Brazil
  • Projected Revenue of ED Treatment Market in Mexico
  • Projected Revenue of ED Treatment Market in Argentina
  • Middle East & Africa: Projected Revenue of ED Treatment Market (2023-2029; $Millions)
  • Projected Revenue of ED Treatment Market in Saudi Arabia
  • Projected Revenue of ED Treatment Market in South Africa
  • Projected Revenue of ED Treatment Market in Turkey

CHAPTER 5: ED Treatment Market Prospects & Opportunities

  • ED Treatment Market Opportunities & Trends
  • ED Treatment Market Drivers
  • ED Treatment Market Constraints

CHAPTER 6:  ED Treatment Industry Overview

  • ED Treatment Market - Competitive Landscape
  • ED Treatment Market – Key Vendor Profiles
  • ED Treatment Market – Other Prominent Vendors
  • ED Treatment Market - Key Strategic Recommendations

CHAPTER 7: Appendix

  • Research Methodology
  • Abbreviations
  • About Arizton

List of Exhibits

Exhibit 1: Projected Revenues of ED Treatment in Global (2023-2029; $ Mn)

Exhibit 2: Projected Revenue of ED Treatment by Drugs (2023-2029; $ Mn)

Exhibit 3: Projected Revenue of ED Treatment by Oral Drugs ($ Mn)

Exhibit 4: Projected Revenues of ED Treatment by Penile Injections (2023-2029; $ Mn)

Exhibit 5: Projected Revenues of ED Treatment by Topical Drugs (2023-2029; $ Mn)

Exhibit 6: Projected Revenues of ED Treatment by Retail Stores (2023-2029; $ Mn)

Exhibit 7: Projected Revenues of ED Treatment by Hospital Pharmacies (2023-2029; $ Mn)

Exhibit 8: Projected Revenues of ED Treatment by Online Portals (2023-2029; $ Mn)

Exhibit 9: Projected Revenue of ED Treatment by Devices (2023-2029; $ Mn)

Exhibit 10: Projected Revenues of ED Treatment by Penile Implants (2023-2029; $ Mn)

Exhibit 11: Projected Revenues of ED Treatment by Vacuum Construction Devices (2023-2029; $ Mn)

Exhibit 12: Projected Revenues of ED Treatment by Shock Wave Therapy (2023-2029; $ Mn)

Exhibit 13: Projected Revenues of ED Treatment by Others (2023-2029; $ Mn)

Exhibit 14: Projected Revenues of ED Treatment in North America (2023-2029; $ Mn)

Exhibit 15: Projected Revenues of ED Treatment in the US (2023-2029; $ Mn)

Exhibit 16: Projected Revenues of ED Treatment in Canada (2023-2029; $ Mn)

Exhibit 17: Projected Revenues of ED Treatment in Europe (2023-2029; $ Mn)

Exhibit 18: Projected Revenues of ED Treatment in the UK (2023-2029; $ Mn)

Exhibit 19: Projected Revenues of ED Treatment in Germany (2023-2029; $ Mn)

Exhibit 20: Projected Revenues of ED Treatment in France (2023-2029; $ Mn)

Exhibit 21: Projected Revenues of ED Treatment in Italy (2023-2029; $ Mn)

Exhibit 22: Projected Revenues of ED Treatment in Spain (2023-2029; $ Mn)

Exhibit 23: Projected Revenues of ED Treatment in APAC (2023-2029; $ Mn)

Exhibit 24: Projected Revenues of ED Treatment in Japan (2023-2029; $ Mn)

Exhibit 25: Projected Revenues of ED Treatment in China (2023-2029; $ Mn)

Exhibit 26: Projected Revenues of ED Treatment in India (2023-2029; $ Mn)

Exhibit 27: Projected Revenues of ED Treatment in Latin America (2023-2029; $ Mn)

Exhibit 28: Projected Revenues of ED Treatment in Brazil (2023-2029; $ Mn)

Exhibit 29: Projected Revenues of ED Treatment in Mexico (2023-2029; $ Mn)

Exhibit 30: Projected Revenues of ED Treatment in Argentina (2023-2029; $ Mn)

Exhibit 31: Projected Revenues of ED Treatment in MEA (2023-2029; $ Mn)

Exhibit 32: Projected Revenues of ED Treatment in Saudi Arabia (2023-2029; $ Mn)

Exhibit 33: Projected Revenues of ED Treatment in South Africa (2023-2029; $ Mn)

Exhibit 34: Projected Revenues of ED Treatment in Turkey (2023-2029; $ Mn)

List of Tables

Table 1: Key Market Trends in ED Treatment Market

Table 2: Key Market Enablers in ED Treatment Market

Table 3: Key Market Constraints in ED Treatment Market

Table 4: Strategic Recommendations in ED Treatment Market

Select a license type that suits your business needs

single-user Single User Licence
$2990.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$3500.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$4500.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date